To determine whether this is also the case with PODXL epitopes, PODO83 and PODO447 tumor H-scores were evaluated in pre-chemotherapy (naïve), post-neoadjuvant chemotherapy (NACT) and recurrent post-chemotherapy tumors in three different cohorts (Figure 3 and Table 2). This evidence concerns the gene PODXL and neoplasm.